Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease

被引：0
|
作者：
Peter Lockwood
Wayne Ewy
David Hermann
Nick Holford
机构：
[1] Pfizer Global Research and Development,Department of Pharmacology and Clinical Pharmacology, School of Medicine
[2] deCODE genetics,undefined
[3] University of Auckland,undefined
来源：
Pharmaceutical Research | 2006年 / 23卷
关键词：
Alzheimer's disease; clinical trial simulation; pharmacokinetic pharmacodynamic model; trial design;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Proof-of-concept clinical trial on the use of oral ridaforolimus, an investigational mTOR inhibitor, for enhanced autophagy in Parkinson's disease
    Machado, D. G.
    Jabbari, B.
    MOVEMENT DISORDERS, 2010, 25 (07) : S300 - S300
  • [22] The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial
    Burns, Daniel K.
    Chiang, Carl
    Welsh-Bohmer, Kathleen A.
    Brannan, Stephen K.
    Culp, Meredith
    O'Neil, Janet
    Runyan, Grant
    Harrigan, Patrick
    Plassman, Brenda L.
    Lutz, Michael
    Lai, Eric
    Haneline, Stephen
    Yarnall, David
    Yarbrough, Deborah
    Metz, Craig
    Ponduru, Sridevi
    Sundseth, Scott
    Saunders, Ann M.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) : 661 - 670
  • [23] Deep learning vs conventional learning algorithms for clinical prediction in Crohn's disease: A proof-of-concept study
    Danny Con
    Daniel R van Langenberg
    Abhinav Vasudevan
    World Journal of Gastroenterology, 2021, 27 (38) : 6476 - 6488
  • [24] Deep learning vs conventional learning algorithms for clinical prediction in Crohn's disease: A proof-of-concept study
    Con, Danny
    van Langenberg, Daniel R.
    Vasudevan, Abhinav
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (38) : 6476 - 6488
  • [25] A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
    Chad J. Swanson
    Yong Zhang
    Shobha Dhadda
    Jinping Wang
    June Kaplow
    Robert Y. K. Lai
    Lars Lannfelt
    Heather Bradley
    Martin Rabe
    Akihiko Koyama
    Larisa Reyderman
    Donald A. Berry
    Scott Berry
    Robert Gordon
    Lynn D. Kramer
    Jeffrey L. Cummings
    Alzheimer's Research & Therapy, 13
  • [26] A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
    Swanson, Chad J.
    Zhang, Yong
    Dhadda, Shobha
    Wang, Jinping
    Kaplow, June
    Lai, Robert Y. K.
    Lannfelt, Lars
    Bradley, Heather
    Rabe, Martin
    Koyama, Akihiko
    Reyderman, Larisa
    Berry, Donald A.
    Berry, Scott
    Gordon, Robert
    Kramer, Lynn D.
    Cummings, Jeffrey L.
    ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
  • [27] Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study
    So Hee Park
    Kyoungwon Baik
    Seun Jeon
    Won Seok Chang
    Byoung Seok Ye
    Jin Woo Chang
    Translational Neurodegeneration, 10
  • [28] Nucleoside Reverse Transcriptase Inhibitor Exposure Is Associated with Lower Alzheimer's Disease Risk: A Retrospective Cohort Proof-of-Concept Study
    Chow, Tiffany W.
    Raupp, Mark
    Reynolds, Matthew W.
    Li, Siying
    Kaeser, Gwendolyn E.
    Chun, Jerold
    PHARMACEUTICALS, 2024, 17 (04)
  • [29] Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
    Chad J. Swanson
    Yong Zhang
    Shobha Dhadda
    Jinping Wang
    June Kaplow
    Robert Y. K. Lai
    Lars Lannfelt
    Heather Bradley
    Martin Rabe
    Akihiko Koyama
    Larisa Reyderman
    Donald A. Berry
    Scott Berry
    Robert Gordon
    Lynn D. Kramer
    Jeffrey L. Cummings
    Alzheimer's Research & Therapy, 14
  • [30] CLINICAL TRIAL SIMULATIONS IN ALZHEIMER'S DISEASE: EXAMPLE APPLICATIONS OF A MODELING AND SIMULATION TOOL IN DRUG DEVELOPMENT.
    Qiu, R.
    Rogers, J.
    Polhamus, D.
    Romero, K.
    Ito, K.
    Corrigan, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S127 - S128
12345